IGC logo

IGC PHARMA INC

IGCNYSE AMERICAN
🏆 #4546 by market capUS Equity
——
Quote unavailable
🔔
Track IGC
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$26M
Small Cap
📈Revenue Growth (YoY)
-6.7%
Declining
📊Gross Margin
21.9%
Moderate
💵FCF Margin
-543.4%
Thin
⚖️P/S Ratio
22.8x
Expensive
Otter Score
—
Insufficient data
No chart data available for IGC.

Trading Snapshot

Day Range
—
52-Week Range
$0.24 – $0.45
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
103.4M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$265,000
P/E Ratio
-3.0
P/S Ratio
22.8x
EPS (TTM)
$-0.08
Dividend Yield
0.00%
Dilution (1yr)
+5.6%
IGC logo

IGC PHARMA INC

IGC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M▼ −6.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
29.7%▼ −39.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$10M▲ +37.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$6M▲ +15.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
100.3M▲ +5.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$751K▼ −$2M YoY
StockOtter · stockotter.space

About IGC PHARMA INC

IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.